ArticleGE Portuguese journal of gastroenterology2025
Adhering to the Barcelona Clinic Liver Cancer Disease Staging and Treatment Algorithm: Disease Burden and Cost of Illness of Hepatocellular Carcinoma in Portugal.
Article in GE Portuguese journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to assess disease burden and cost of illness of hepatocellular carcinoma (HCC) in Portugal, assuming full adherence to the treatment algorithm associated to the Barcelona Clinic Liver Cancer (BCLC) system. Methods: An individual-level, continuous-time, state-transition model was used to simulate the progression of HCC patients through the BCLC disease stages. Health state transition rates were derived from the published literature. An expert panel provided further information on Portuguese epidemiology and clinical practice, including treatments and other healthcare resources utilization at each disease stage. Unit costs for health resources were collected from national public sources. HCC associated costs and outcomes were estimated over a 5-year time horizon. Results: Over the 5-year horizon of this study, the projections of HCC annual prevalence (including patients in remission) show an increasing trend, rising from 4,151 in 2023 to 4,851 in 2027. Despite the slight reduction in the predicted annual mortality rate (from 29.8% to 28.7%), we estimated that HCC could still lead to a total of 120,314 years of life lost due to premature mortality in the Portuguese population. Costs attributed to HCC were predicted to rise from around EUR 70 million in 2023 up to around EUR 77 million in 2027. Around 44.3% of these costs are related to HCC systemic treatment and 29.0% related to liver transplantation costs. Conclusion: HCC's increasing prevalence trend will continue to impose substantial disease burden in terms of premature mortality, with more than 20,000 years of life lost per year in the Portuguese population. Consequently, costs attributed to HCC are expected to rise despite the reduction on mortality by full adherence to the BCLC treatment algorithm. Continuing high disease burden and substantial cost of illness urge for a need of a comprehensive and effective healthcare interventions, as well as adequate resource allocation for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.